Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Working Life
Candidate-short market plagues recruiters
A lack of suitable candidates to fill agency-advertised roles in the Australian pharma market was the major issue to emerge from a survey of pharma company use of external recruitment firms.
Approvals Action
Generics, OTCs make the running
The generics and over-the-counter ectors made the running on the drugs register during the week, which was a quiet one for new prescription drug approvals.
PBS Top Five
Rheumatology & MSK: a fast-growing market
The market for PBS subsidised rheumatology and musculoskeletal drugs is growing at close to 11 per cent a year according to the latest figures with on-patent drugs growing even faster at 16 per cent.
Pipeline Monitor
Takeda files Velcade successor
Takeda's filing of oral multiple myeloma treatment ixazomib has been accepted in Europe while Novartis has won US extension of Promacta.
Special Report
Your guide to the November PBAC
The PBAC will consider 33 major submissions including 18 for new listings when it next meets in November. See the full agenda, sorted by indication, inside.
Special Report
Inflectra not the only game in PBAC town
Although a positive recommendation for Inflectra has been the focus of attention on Friday's PBAC outcomes, the meeting made other important recommendations as well as rejecting a number of contentious submissions. Here's the list of outcomes sorted by submission type and indication.